Trial Profile
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 May 2023 Planned End Date changed from 5 Oct 2023 to 9 Apr 2024.
- 17 May 2023 Planned primary completion date changed from 5 Oct 2023 to 9 Apr 2024.
- 30 Mar 2023 Planned End Date changed from 11 Apr 2023 to 5 Oct 2023.